Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: A meta-analysis

Indian Journal of Gastroenterology

Volumn 31, Issue 2, 2012, Pages 69-74

  Ashraf, Imran ^a   Choudhary, Abhishek ^a   Arif, Murtaza ^a   Matteson, Michelle L ^a   Hammad, Hazem T ^a   Puli, Srinivas R ^b   Bechtold, Matthew L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b OSF MG Gastroenterology   (United States)

Author keywords

Chemoprevention; Colorectal cancer; Primary sclerosing cholangitis; Ulcerative colitis; Ursodeoxycholic acid; Ursodiol

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; COLON ADENOMA; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PRIMARY SCLEROSING CHOLANGITIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADENOMA; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COLITIS, ULCERATIVE; COLONIC NEOPLASMS; HUMANS; URSODEOXYCHOLIC ACID;

EID: 84862021487     PISSN: 02548860     EISSN: 09750711     Source Type: Journal    
DOI: 10.1007/s12664-012-0175-3     Document Type: Article

References (43)

1. Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centers. Gut. 1988; 29: 206-7.
2. Lennard-Jones JE. Cancer risk in ulcerative colitis: surveillance or surgery. Br J Surg. 1985; 72 Suppl: S84-6.
3. Collins Jr RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis. A critical review. N Eng J Med. 1987; 316: 1654-8.
4. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990; 323: 1228-33.
5. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses Jr AH, Greenstein AJ. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut. 1991; 32: 167-9.
6. Broomé U, Lindberg G, Lofberg R. Primary sclerosing cholangitis in ulcerative colitis-a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology. 1992; 102: 1877-80.
7. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med. 1995; 332: 924-33.
8. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002; 56: 48-54.
9. Reddy BS, Wynder EL. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer. 1977; 39: 2533-9.
10. Moorehead RJ, Campbell GR, Donaldson JD, McKelvey ST. Relationship between duodenal bile acids and colorectal neoplasia. Gut. 1987; 28: 1454-9.
11. Morvay K, Szentleleki K, Torok G, Pintér A, Börzsönyi M, Nawroth R. Effect of change of fecal bile acid excretion achieved by operative procedures on 1, 2-dimethylhydrazine-induced colon cancer in rats. Dis Colon Rectum. 1989; 32: 860-3.
12. Bayerdorffer E, Mannes GA, Richter WO, et al. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 1993; 104: 145-51.
13. Bayerdorffer E, Mannes GA, Ochsenkuhn T, Dirschedl P, Wiebecke B, Paumgartner G. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 1995; 36: 268-73.
14. Ochsenkuhn T, Bayerdorffer E, Meining A, et al. Colonic mucosal proliferation is related to serum deoxycholic acid levels. Cancer. 1999; 85: 1664-9.
15. Qiao D, Chen W, Stratagoules ED, Martinez JD. Bile acid-induced activation of activator protein-1 requires both extracellular signal-regulated kinase and protein kinase C signaling. J Biol Chem. 2000; 275: 15090-8.
16. Wargovich MJ, Eng VW, Newmark HL, Bruce WR. Calcium ameliorates the toxic effect of deoxycholic acid on colonic epithelium. Carcinogenesis. 1983; 4: 1205-7.
17. Bull AW, Marnett LJ, Dawe EJ, Nigro ND. Stimulation of deoxythymidine incorporation in the colon of rats treated intrarectally with bile acids and fats. Carcinogenesis. 1983; 4: 207-10.
18. Lapre JA, Termont DS, Groen AK, van der Meer R. Lytic effects of mixed micelles of fatty acids and bile acids. Am J Physiol. 1992; 263: G333-7.
19. Friedman EA. A multistage model for human colon carcinoma development from tissue culture studies. In: Ingall JRF, Mastromarino AJ, editors. Carcinoma of the large bowel and its precursors. New York: Alan R. Liss, Inc; 1985. p. 175-86.
20. McMillan L, Butcher S, Wallis Y, Neoptolemos JP, Lord JM. Bile acids reduce the apoptosis-inducing effects of sodium butyrate on human colon adenoma (AA/C1) cells: implications for colon carcinogenesis. Biochem Biophys Res Commun. 2000; 273: 45-9.
21. Martinez JD, Stratagoules ED, LaRue JM, et al. Different bile acids exhibit distinct biological effects: the tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation. Nutr Cancer. 1998; 31: 111-8.
22. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med. 1997; 336: 691-5.
23. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Inhibitory effects of ursodeoxycholic acid on N-methylnitrosourea-induced colon carcinogenesis and colonic mucosal telomerase activity in F344 rats. J Exp Clin Can Res. 1999; 18: 259-66.
24. Narisawa T, Fukaura Y, Terada K, Sekiguchi H. Prevention of N-methylnitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats. Jpn J Cancer Res. 1998; 89: 1009-13.
25. Earnest DL, Holubec H, Wali RK, et al. Chemoprevention of azomethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res. 1994; 54: 5071-4.
26. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 1994; 83: 319-23.
27. Ikegami T, Matsuzaki Y, Shoda J, Kano M, Hirabayashi N, Tanaka N. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue. Cancer Lett. 1998; 134: 129-39.
28. Tung BY, Edmond MJ, Haggitt C, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001; 134: 89-95.
29. Pardi DS, Loftus EV, Kremers WK, Keach J, Lindor KD. Ursodeoxycholic acid acts as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003; 124: 889-93.
30. Qiao D, Stratagouleas ED, Martinez JD. Activation and role of mitogen activated protein kinases in deoxycholic acid-induced apoptosis. Carcinogenesis. 2001; 22: 35-41.
31. Im E, Martinez JD. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr. 2004; 134: 483-6.
32. Sjöqvist U, Tribukait B, Ost A, Einarsson C, Oxelmark L, Löfberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res. 2004; 24: 3121-7.
33. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283: 2008-12.
34. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www. ohri. ca/programs/clinical_epidemiology/oxford. asp.
35. Ullman TA, Croog V, Maratchi L, et al. Ursodeoxycholic acid for chemoprevention in ulcerative colitis and primary sclerosing cholangitis: a retrospective cohort study. Am J Gastroenterol. 2003; 98: S258.
36. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2005; 22: 783-8.
37. Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997; 41: 522-5.
38. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis: the impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001; 444: 77-85.
39. Adler DG, Baron TH, Davila RE, et al. ASGE guideline: the role of ERCP in diseases of the biliary tract and the pancreas. Gastrointest Endosc. 2005; 62: 1-8.
40. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta analysis. Gut. 2001; 48: 526-35.
41. Prior P, Gyde SN, Macartney JC, Waterhouse JA, Allan RN. Cancer morbidity in ulcerative colitis. Gut. 1982; 23: 490-7.
42. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-62.
43. Itzkowitz SH, Present DH. Crohn's and Colitis Foundation of American Colon Cancer in IBD Study Group: consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11: 314-21.